Stopped: insufficient recruitment
This is a one-arm, single site, open-label phase II study. Patients will be enrolled in the screening step at the start of the second line of chemotherapy, and will undergo blood draws for ctDNA detection. Patients for whom ctDNA was successfully detected and found informative by the study executive board could then be included in the interventional step when starting a new line of therapy. ctDNA will be quantified using the customized test, at baseline and day 15 (+/- 3 working day) of cycle #1, and results will be made available before the cycle 2 Day 1, together with a treatment management recommendation by the Study Executive Board (continuation or discontinuation of the corresponding chemotherapy)
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
L3C1 : ctDNA quantification
Timeframe: At the Day 1 of Cycle 1 (each cycle is 21 days)
L3C1 : ctDNA quantification
Timeframe: At the Day 15 of Cycle 1 (each cycle is 21 days)
L3C1 : chemotherapy efficacy
Timeframe: ctDNA difference between Day 15 and Day 1
LxC1 : ctDNA quantification
Timeframe: At the Day 1 of the Cycle 1 (each cycle is 21 days)
LxC1 : ctDNA quantification
Timeframe: At the Day 15 of the Cycle 1 (each cycle is 21 days)
LxC1 : chemotherapy efficacy
Timeframe: ctDNA difference between Day 15 and Day 1
Progression Free Survival (PFS)
Timeframe: From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed every 8-weeks up to 18 months